Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UK Scientists to Begin Trial of Potential HIV Cure

Published: Wednesday, November 27, 2013
Last Updated: Wednesday, November 27, 2013
Bookmark and Share
Scientists and clinicians from five leading UK universities will begin a groundbreaking clinical trial next year to test a possible cure for HIV infection.

The researchers, led by Dr John Frater at Oxford University and Dr Sarah Fidler at Imperial College London, hope the trial will show that a cure is feasible.

'We can only truly know if someone is cured of HIV if we stop giving them antiretroviral therapy,' said Dr Frater of the Nuffield Department of Clinical Medicine at Oxford University. 'We're not going to do that, but we will test if we can reduce the number of HIV-infected cells in these patients. If we can, it will prove in principle that this strategy could work as a cure, even though it will need many more years of further development.'

Efforts to cure HIV in the past have been thwarted by the virus's ability to lie dormant inside blood cells without being detected.

Thirty-four million people are infected by HIV worldwide. Antiretroviral therapy (ART) is highly effective at stopping the virus from reproducing, but it doesn't eradicate the disease, so it has to be taken for life.

The new therapy combines standard antiretroviral drugs with two new weapons: a drug that reactivates dormant HIV, and a vaccine that induces the immune system to destroy the infected cells.

Fifty patients in the early stages of HIV infection will take part in the trial. The researchers hope that within months, the stores of hidden HIV in these patients – called the HIV reservoir – will be significantly reduced. They expect to know the results in 2017.

The trial is being conducted by the CHERUB collaboration – an alliance of HIV researchers at Oxford University, Imperial College London, the University of Cambridge, University College London and King's College London. It is being funded by a £1.7 million grant from the Medical Research Council as part of the Biomedical Catalyst funding stream.

Key preliminary studies by the CHERUB researchers that laid the groundwork for the trial were supported by National Institute for Health Research Biomedical Research Centres based at the five universities and their NHS Trust partners.

HIV carries its genetic code in RNA, a molecule related to DNA, but as part of its lifecycle it copies the code into DNA and merges it with the DNA of human cells it has infected. In some cells this DNA remains dormant enabling it to stay hidden from the immune system and resist therapy.

Drugs called HDAC inhibitors, which are used as cancer treatments, have been shown to reactivate dormant HIV in the laboratory.

One group of patients in the trial will be given a short course of HDAC inhibitors and an HIV vaccine alongside ART. Another group will get ART with placebos.

As part of the study the research team are developing an improved method for detecting latency, which has been one of the difficulties in measuring the success of therapeutic approaches such as this.

'We know that targeting the HIV reservoir is extremely difficult,' said Dr Fidler of Imperial College London, 'but our research in the labs has led to some very promising results. We now have the opportunity to translate that into a possible new treatment, which we hope will be of real benefit to patients.'


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!